Early use of lecanemab by Medicare beneficiaries with Alzheimer’s or mild cognitive impairment is marked by racial, ethnic, ...

Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

The analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab. HealthDay News — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory ...

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer’s disease (AD), has been disproportionately higher among ...

Cassidy’s comments come after Trump signed an executive order to make prescription drug prices in the United States ...

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment ...

Key TakeawaysSerious side effects of lecanemab can be safely managed, researchers sayNo patients died of brain swelling and bleeding due to lecanemabOnly 4% of patients needed to quit lecanemab due to ...

Harley Street, a famous medical district in London, is an unusual place. It is highly successful, accounting for 40% of the ...

The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...